Cargando…

Extracranial dose and the risk of radiation-induced malignancy after intracranial stereotactic radiosurgery: is it time to establish a therapeutic reference level?

BACKGROUND: To measure extracranial doses from Gamma Knife Perfexion (GKP) intracranial stereotactic radiosurgery (SRS) and model the risk of malignancy after SRS for different treatment platforms. METHODS: Doses were measured for 20 patients undergoing SRS on a GKP at distances of 18, 43 and 75 cm...

Descripción completa

Detalles Bibliográficos
Autores principales: Paddick, Ian, Cameron, A., Dimitriadis, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966618/
https://www.ncbi.nlm.nih.gov/pubmed/33325003
http://dx.doi.org/10.1007/s00701-020-04664-4
_version_ 1783665706785570816
author Paddick, Ian
Cameron, A.
Dimitriadis, A.
author_facet Paddick, Ian
Cameron, A.
Dimitriadis, A.
author_sort Paddick, Ian
collection PubMed
description BACKGROUND: To measure extracranial doses from Gamma Knife Perfexion (GKP) intracranial stereotactic radiosurgery (SRS) and model the risk of malignancy after SRS for different treatment platforms. METHODS: Doses were measured for 20 patients undergoing SRS on a GKP at distances of 18, 43 and 75 cm from the target, corresponding to the approximate positions of the thyroid, breast and gonads respectively. A literature review was conducted to collect comparative data from other radiosurgery platforms. All data was used to calculate the dose to body organs. The National Cancer Institute (NCI) RadRAT calculator was used to estimate excess lifetime cancer risk from this exposure. Five different age groups covering childhood and younger adults were modelled for both sexes. RESULTS: Extracranial doses delivered during SRS with the GKP were a median 0.04%, 0.008% and 0.002% of prescription dose at 18 cm, 43 cm and 70 cm from the isocentre respectively. Comparison with the literature revealed that the extracranial dose was lowest from GKP, then linacs equipped with micro-multileaf collimators (mMLC), then linacs equipped with circular collimators (cones), and highest from Cyberknife (CK). Estimated lifetime risks of radiation-induced malignancy in the body for patients treated with SRS aged 5–45 years were 0.03–0.88%, 0.36–11%, 0.61–18% and 2.2–39% for GKP, mMLC, cones and CK respectively. CONCLUSIONS: We have compared typical extracranial doses from different platforms and quantified the lifetime risk of radiation-induced malignancy. The risk varies with platform. This should be taken into account when treating children and young adults with SRS. The concept of a therapeutic reference level (TRL), similar to the diagnostic reference level (DRL) established in radiology, is proposed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00701-020-04664-4.
format Online
Article
Text
id pubmed-7966618
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-79666182021-04-01 Extracranial dose and the risk of radiation-induced malignancy after intracranial stereotactic radiosurgery: is it time to establish a therapeutic reference level? Paddick, Ian Cameron, A. Dimitriadis, A. Acta Neurochir (Wien) Original Article - Brain Tumors BACKGROUND: To measure extracranial doses from Gamma Knife Perfexion (GKP) intracranial stereotactic radiosurgery (SRS) and model the risk of malignancy after SRS for different treatment platforms. METHODS: Doses were measured for 20 patients undergoing SRS on a GKP at distances of 18, 43 and 75 cm from the target, corresponding to the approximate positions of the thyroid, breast and gonads respectively. A literature review was conducted to collect comparative data from other radiosurgery platforms. All data was used to calculate the dose to body organs. The National Cancer Institute (NCI) RadRAT calculator was used to estimate excess lifetime cancer risk from this exposure. Five different age groups covering childhood and younger adults were modelled for both sexes. RESULTS: Extracranial doses delivered during SRS with the GKP were a median 0.04%, 0.008% and 0.002% of prescription dose at 18 cm, 43 cm and 70 cm from the isocentre respectively. Comparison with the literature revealed that the extracranial dose was lowest from GKP, then linacs equipped with micro-multileaf collimators (mMLC), then linacs equipped with circular collimators (cones), and highest from Cyberknife (CK). Estimated lifetime risks of radiation-induced malignancy in the body for patients treated with SRS aged 5–45 years were 0.03–0.88%, 0.36–11%, 0.61–18% and 2.2–39% for GKP, mMLC, cones and CK respectively. CONCLUSIONS: We have compared typical extracranial doses from different platforms and quantified the lifetime risk of radiation-induced malignancy. The risk varies with platform. This should be taken into account when treating children and young adults with SRS. The concept of a therapeutic reference level (TRL), similar to the diagnostic reference level (DRL) established in radiology, is proposed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00701-020-04664-4. Springer Vienna 2020-12-15 2021 /pmc/articles/PMC7966618/ /pubmed/33325003 http://dx.doi.org/10.1007/s00701-020-04664-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article - Brain Tumors
Paddick, Ian
Cameron, A.
Dimitriadis, A.
Extracranial dose and the risk of radiation-induced malignancy after intracranial stereotactic radiosurgery: is it time to establish a therapeutic reference level?
title Extracranial dose and the risk of radiation-induced malignancy after intracranial stereotactic radiosurgery: is it time to establish a therapeutic reference level?
title_full Extracranial dose and the risk of radiation-induced malignancy after intracranial stereotactic radiosurgery: is it time to establish a therapeutic reference level?
title_fullStr Extracranial dose and the risk of radiation-induced malignancy after intracranial stereotactic radiosurgery: is it time to establish a therapeutic reference level?
title_full_unstemmed Extracranial dose and the risk of radiation-induced malignancy after intracranial stereotactic radiosurgery: is it time to establish a therapeutic reference level?
title_short Extracranial dose and the risk of radiation-induced malignancy after intracranial stereotactic radiosurgery: is it time to establish a therapeutic reference level?
title_sort extracranial dose and the risk of radiation-induced malignancy after intracranial stereotactic radiosurgery: is it time to establish a therapeutic reference level?
topic Original Article - Brain Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966618/
https://www.ncbi.nlm.nih.gov/pubmed/33325003
http://dx.doi.org/10.1007/s00701-020-04664-4
work_keys_str_mv AT paddickian extracranialdoseandtheriskofradiationinducedmalignancyafterintracranialstereotacticradiosurgeryisittimetoestablishatherapeuticreferencelevel
AT camerona extracranialdoseandtheriskofradiationinducedmalignancyafterintracranialstereotacticradiosurgeryisittimetoestablishatherapeuticreferencelevel
AT dimitriadisa extracranialdoseandtheriskofradiationinducedmalignancyafterintracranialstereotacticradiosurgeryisittimetoestablishatherapeuticreferencelevel